Chronic Leukemia — Trials

Chronic Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

1,705 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 411
Recruiting: 207
Ph III recruiting: 22
Growth YoY: −13.3%
Industry share: 28%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 32.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (302)

clinicaltrialsPublishedShowing 1–9 of 9 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02612311	Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia(UNITY-CLL)	terminated	Phase 3	603	TG Therapeutics, Inc.INDUSTRY	7	Dec 13, 2024	clinicaltrials
NCT03801525	Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)(ULTRA-V)	terminated	Phase 2 / Phase 3	277	TG Therapeutics, Inc.